“Only six of the 50 anti-bacterials currently in the pipeline meet even one criterion for being innovative. Most of the antimicrobials approved recently offer little to no added clinical value ...

It was around this point that AZ decided to re-focus its disease area research with infection and anti-bacterials as one of its key therapy areas. AstraZeneca was one of the top ten pharmaceutical ...